US2017136067A1PendingUtilityA1

Methods of using regenerative cells in the treatment of musculoskeletal disorders

62
Assignee: CYTORI THERAPEUTICS INCPriority: Dec 7, 2001Filed: Nov 28, 2016Published: May 18, 2017
Est. expiryDec 7, 2021(expired)· nominal 20-yr term from priority
A61L 27/3834A61L 27/3691A61L 2300/412A61L 2430/40A61L 27/3847C12N 5/0667A61L 27/3895A61L 2430/06A61L 27/54A61L 2300/64A61K 35/28A61P 19/08A61L 2430/02A61L 27/18A61L 27/52A61L 27/56A61P 19/04A61L 27/3608A61L 2300/40A61L 27/3654A61L 27/365A61L 27/3852A61L 2400/06A61P 19/02
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of treating a patient, comprising:
 (a) providing a tissue removal system;   (b) removing adipose tissue from a patient using the tissue removal system, the adipose tissue having a concentration of stem cells;   (c) processing at least a part of the adipose tissue to obtain a concentration of stem cells other than the concentration of stem cells of the adipose tissue before processing; and   (d) administering the stem cells to a patient without removing the stem cells from the tissue removal system before being administered to the patient.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.